October 24, 2019

Prof. Arndt Rolfs, MD
Chief Executive Officer
Centogene B.V.
Am Strande 7
18055 Rostock

       Re: Centogene B.V.
           Registration Statement on Form F-1
           Filed October 11, 2019
           File No. 333-234177

Dear Prof. Arndt Rolfs:

       We have reviewed your registration statement and have the following
comments. In
some of our comments, we may ask you to provide us with information so we may
understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
circumstances or do not believe an amendment is appropriate, please tell us why
in your

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form F-1 filed October 11, 2019


1.     We note your disclosure that certain existing stockholders have
indicated an interest to
       purchase up to a specific amount of common stock in the offering. We
also note your
       disclosure that such stockholders may purchase more than the amount for
which they
       indicated an interest in buying. So that investors will be able to
understand the minimum
       amount of your shares that will enter the public market through sales to
the public, as
       opposed to the existing stockholders, please disclose whether there is a
ceiling on the
       amount that may be purchased by existing stockholders and quantify any
ceiling. If not,
 Prof. Arndt Rolfs, MD
Centogene B.V.
October 24, 2019
Page 2
      please disclose the potential material impact on the public investors.
Additionally, please
      tell us whether the limited number of public investors would impact the
company's listing
2.    We note your disclosure that any of the stockholders that have indicated
an interest in
      buying shares in the offering may determine to purchase more, less or no
shares in this
      offering. If material, please add a risk factor describing the risks
related to the offering.
3.    Please identify the existing stockholders and the number of shares that
these stockholders
      have indicated an interest in purchasing in the offering.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration

       You may contact Jonathan Burr at 202-551-5833 or Brigitte Lippmann at
with any questions.

FirstName LastNameProf. Arndt Rolfs, MD
                                                              Division of
Corporation Finance
Comapany NameCentogene B.V.
                                                              Office of Real
Estate & Construction
October 24, 2019 Page 2
cc:       Leo Borchardt
FirstName LastName